Interestingly, decreased expression of ATRNL1 (logrank P = 0.0037) and GFRA1 (logrank P = 0.081) is associated with reduced overall survival in a cohort of ER+ breast cancer patients treated with endocrine therapy (Supplementary Fig. 6c, d)24. Here, ATRNL1 is linked to breast carcinoma.